Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab in COVID-19 Pneumonia
NCT04275245Phase 2Completed
- Sponsor
- Tangdu Hospital
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of meplazumab in coronavirus disease 2019 (COVID-19), sponsored by Tangdu Hospital. Primary endpoint: 2019 nCoV nucleic acid detection at 14 days. Started Feb 2020; status: completed.
02
Drugs
meplazumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04275245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275245.